Agilent A

Agilent Technologies, Inc. is navigating recent market challenges while maintaining strong investor confidence. Despite a 6% drop in shares and ongoing tariff pressures, it has been upgraded to a Zacks Rank #2, with projected earnings of $5.95 per share for the fiscal year ending October 2026. The company achieved $6.95 billion in revenue for 2025, supported by its FDA-approved PD-L1 IHC 22C3 assay, although it faces concerns owing to a 12.8% decline in year-to-date performance. Agilent is also planning a strategic split into two independent entities to enhance operational focus, amidst expectations of sustained growth in the biotech sector.